drugset / Trial / NCT03451227

Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures

NCT03451227 ↗

Terminated 6 enrolled University Health Network, Toronto
RandomizedParallel-groupDouble-blindBasic science

Summary

To evaluate the safety and efficacy of dexmedetomidine and compare this to a current technique commonly used at TGH for sedation in patients undergoing ablation procedures for atrial fibrillation (AF) and atrial flutter. The investigators hypothesise that dexmedetomidine will be at least equivalent to, or more so, in terms of effectiveness and safety, when compared to midazolam and remifentanil for sedation during ablation procedures.

Timeline

Start
2017-12-01
Primary completion
2018-03-12
Completion
2019-05-14

Outcome

Outcome not reported

Stopped (Enrollment): “Unable to recruit eligible participants”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.2 ug/kg —
Subject Dexmedetomidine Other / unclassified 1 ug/kg —
Comparator Remifentanil Small molecule 0.01 ug/kg —
Comparator Remifentanil Small molecule 0.2 ug/kg —